Current Challenges in the Management of Tuberculosis

The global fight against Tuberculosis (TB) persists; grappling with approximately 10.6 million new cases in 2021, as documented in the 2022 WHO Global TB Report.1 Of concern is the escalating incidence of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB), which saw an estimated 450,000 new cases in the same year. Today's major problem in the treatment of Mycobacterium TB is drug resistance brought on by anti-TB therapy. The degree of resistance led to variations and other effects that eventually ended in death and health risks. The advent of certain drug-resistant strains of TB that are resistant to several treatments, prolonged drugs and all drugs is going to bring a major and catastrophic comeback to the disease. Current advancements in TB treatment help to reduce anti-tubercular medication resistance. Due to Mycobacterium tuberculosis's extraordinary flexibility, drug resistance in tuberculosis is a complicated phenomenon. Via genetic mutations, efflux pumps and other processes, these bacteria may become resistant to anti-TB medications. Hence, against drug-resistant bacteria, conventional TB treatment regimens-which usually include a mix of antibiotics-may stop working. The worldwide account will lose about 200,000 due to medication resistance fatalities in a single year. The development of vaccines against tuberculosis is a promising topic, but progress has been hampered by a lack of funding, organization and understanding of immunological responses. A Tubercular Vaccine Accelerator Council will combine resources and expertise to tackle these issues and accelerate development. Accomplish the WHO's goal of TB eradication by 2030.